{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:10:42Z","timestamp":1780330242699,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["(2018ZX10711-001)(2017YFA0205100)"],"award-info":[{"award-number":["(2018ZX10711-001)(2017YFA0205100)"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The development of rapid serological detection methods re urgently needed for determination of neutralizing antibodies in sera. In this study, four rapid methods (ACE2-RBD inhibition assay, S1-IgG detection, RBD-IgG detection, and N-IgG detection) were established and evaluated based on chemiluminescence technology. For the first time, a broadly neutralizing antibody with high affinity was used as a standard for the quantitative detection of SARS-CoV-2 specific neutralizing antibodies in human sera. Sera from COVID-19 convalescent patients (N = 119), vaccinated donors (N = 86), and healthy donors (N = 299) confirmed by microneutralization test (MNT) were used to evaluate the above methods. The result showed that the ACE2-RBD inhibition assay calculated with either ACE2-RBD binding inhibition percentage rate or ACE2-RBD inhibiting antibody concentration were strongly correlated with MNT (r \u2265 0.78, p &lt; 0.0001) and also highly consistent with MNT (Kappa Value \u2265 0.94, p &lt; 0.01). There was also a strong correlation between the two evaluation indices (r \u2265 0.99, p &lt; 0.0001). Meanwhile, S1-IgG and RBD-IgG quantitative detection were also significantly correlated with MNT (r \u2265 0.73, p &lt; 0.0001), and both methods were highly correlated with each other (r \u2265 0.95, p &lt; 0.0001). However, the concentration of N-IgG antibodies showed a lower correlation with the MNT results (r &lt; 0.49, p &lt; 0.0001). The diagnostic assays presented here could be used for the evaluation of SARS-CoV-2 vaccine immunization effect and serological diagnosis of COVID-19 patients, and could also have guiding significance for establishing other rapid serological methods to surrogate neutralization tests for SARS-CoV-2.<\/jats:p>","DOI":"10.3390\/v13081508","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T21:46:44Z","timestamp":1627854404000},"page":"1508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population"],"prefix":"10.3390","volume":"13","author":[{"given":"Qiangling","family":"Yin","sequence":"first","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-7262","authenticated-orcid":false,"given":"Yecheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Lian","sequence":"additional","affiliation":[{"name":"Innovita Biological Technology Co., Ltd., Beijing 100070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Qu","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Pei","sequence":"additional","affiliation":[{"name":"Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyou","family":"Chen","sequence":"additional","affiliation":[{"name":"Innovita Biological Technology Co., Ltd., Beijing 100070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqian","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"},{"name":"CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxiang","family":"Guan","sequence":"additional","affiliation":[{"name":"Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China"},{"name":"CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mifang","family":"Liang","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"},{"name":"CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, June 08). WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.molmed.2020.02.008","article-title":"COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives","volume":"26","author":"Sun","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","article-title":"Structural basis for human coronavirus attachment to sialic acid receptors","volume":"26","author":"Tortorici","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.4049\/jimmunol.2000767","article-title":"Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19","volume":"205","author":"Vogelzang","year":"2020","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., and Kellam, P. (2020). Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15.","DOI":"10.1101\/2020.08.25.20178806"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ofid\/ofaa387","article-title":"The Antibody Response to SARS-CoV-2 Infection","volume":"7","author":"Hueston","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3201\/eid2610.202211","article-title":"Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients","volume":"26","author":"Choe","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of Human Single-Domain Antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pinto, D., Park, Y.-J., Beltramello, M., Walls, A., Tortorici, M.A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., and De Marco, A. (2020). Structural and functional analysis of a potent sarbecovirus neutralizing antibody. BioRxiv.","DOI":"10.2210\/pdb6ws6\/pdb"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14712590902763755","article-title":"Potent Human Monoclonal Antibodies Against SARS CoV, Nipah and Hendra Viruses","volume":"9","author":"Prabakaran","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_15","unstructured":"Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., and Yang, Y. (2020). A Potent Neutralizing Human Antibody Reveals the N-Terminal Domain of the Spike Protein of Sars-Cov-2 as a Site of Vulnerability. BioRxiv, Available online: https:\/\/www.biorxiv.org\/content\/biorxiv\/early\/2020\/05\/08\/2020.05.08.083964.full.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41467-021-21609-2","article-title":"SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface","volume":"12","author":"Bertoglio","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMp2029466","article-title":"Vaccine Innovations\u2014Past and Future","volume":"384","author":"Gerberding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","unstructured":"World Health Organization (2021, May 21). Draft Landscape and Tracker of COVID-19 Candidate Vaccines. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_20","unstructured":"(2021, July 17). Our World in Data Total Number of COVID-19 Vaccinations Administered. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/clinchem\/29.9.1604","article-title":"Homogeneous immunoassay based on chemiluminescence energy transfer","volume":"29","author":"Patel","year":"1983","journal-title":"Clin. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1016\/j.vaccine.2012.06.037","article-title":"Evaluation of a new serological technique for detecting rabies virus antibodies following vaccination","volume":"30","author":"Ma","year":"2012","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, Y.F., and Kobayashi, M. (2013). Antibody Detection: Principles and Applications. Adv. Tech. Diagn. Microbiol., 53\u201373.","DOI":"10.1007\/978-1-4614-3970-7_4"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-017-0097-2","article-title":"Chemiluminescent immunoassay technology: What does it change in autoantibody detection?","volume":"8","author":"Cinquanta","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"ref_27","unstructured":"Hou, J., Sun, W., Huang, G., Zhan, X., and Yang, M. (2020). Prokaryotic Soluble Expression and Serological Evaluation of SARS-CoV-2 N Protein. J. Lett. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Qu, Y., Zhang, X., Wang, M., Sun, L., Jiang, Y., Li, C., Wu, W., Chen, Z., Yin, Q., and Jiang, X. (2021). Antibody Cocktail Exhibits Broad Neutralization Against Sars-Cov-2 and Sars-Cov-2 Variants. BioRxiv, Available online: https:\/\/www.biorxiv.org\/content\/biorxiv\/early\/2021\/04\/17\/2021.04.16.440083.full.pdf.","DOI":"10.1101\/2021.04.16.440083"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41590-020-0788-0","article-title":"Author Correction: ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection","volume":"21","author":"Hachim","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_31","unstructured":"Liu, Y., Soh, W.T., Tada, A., Arakawa, A., Matsuoka, S., Nakayama, E.E., Li, S., Ono, C., Torii, S., and Kishida, K. (2020). An Infectivity-Enhancing Site on the Sars-Cov-2 Spike Protein is Targeted by COVID-19 Patient Antibodies. BioRxiv, Available online: https:\/\/www.biorxiv.org\/content\/biorxiv\/early\/2020\/12\/18\/2020.12.18.423358.full.pdf."},{"key":"ref_32","unstructured":"Our World in Data (2021, May 27). Vaccine Development: Vaccines Approved for Use and in Clinical Trials. Available online: https:\/\/ourworldindata.org\/covid-vaccinations#source-information-country-by-country."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:37:55Z","timestamp":1760164675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081508"],"URL":"https:\/\/doi.org\/10.3390\/v13081508","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]}}}